Georgia Bio Innovation Summit
At Georgia Bio, let’s discuss how Recro will exceed expectations for your most complex challenges in solid oral dose formulation and manufacturing — concept to clinic to commercial. DEA controlled substances? No problem. Demand more from your CDMO.
And listen to Wayne Wiley, our VP of regulatory affairs and pharmacovigilance, share his experience in the 2:00 PM (TRACK B) session on business growth: Advancing from ‘R’ to ‘D’ to ‘C’: Various Routes to Building Successful Clinical Stage Companies.